National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

< Back to Main

Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Browse by Cancer Type
Breast Cancer

Lung Cancer

Prostate Cancer

More Results
Search Trial Results

    Search  
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

Denosumab May Help Prevent Bone Loss

Past Highlights
Related Pages
Colon and Rectal Cancer Home Page
NCI's gateway for information about colon and rectal cancer.

Search for Clinical Trials
NCI's PDQ® registry of cancer clinical trials.
Colon and Rectal Cancer Trial Results
1.  Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
(Posted: 09/17/2008) - Computerized tomographic colonography, also known as virtual colonoscopy, is comparable to standard colonoscopy, which uses a long, flexible tube with a camera to view the lining of the colon, in its ability to accurately detect cancer and precancerous polyps and could serve as an initial screening exam for colorectal cancer, according to the results of the American College of Radiology Imaging Network National CT Colonography Trial.

2.  Colorectal Cancer Drugs Require Careful Patient Selection
(Posted: 06/18/2008) - Patients with advanced colorectal cancer who have mutant forms of the gene KRAS in their tumors should not receive chemotherapy plus cetuximab (Erbitux), because they are unlikely to benefit from the treatment, according to findings presented at the 2008 ASCO meeting in Chicago.

3.  Celecoxib Reduces Risk of Precancerous Colorectal Polyps: Five-Year Results of APC Trial
(Posted: 04/23/2008) - The five-year results of the Adenoma Prevention with Celecoxib (APC) trial indicate that two years after daily use of celecoxib (Celebrex®) has ended, there continues to be a modest reduction in the recurrence of colorectal polyps, according to a presentation at the 2008 American Association for Cancer Research annual meeting.

4.  Drug Combination Cuts Risk of Advanced Colon Polyps
(Posted: 04/21/2008) - Low doses of two chemopreventive agents are highly effective at preventing the recurrence of the lesions that are often precursors to colorectal cancer, according to results presented at the 2008 American Association for Cancer Research annual meeting.

5.  Cetuximab Provides Slight Survival Advantage in Advanced Colorectal Cancer
(Posted: 11/27/2007) - Use of the targeted agent cetuximab (Erbitux®) provides a small, but statistically significant improvement in overall survival in patients with colorectal cancer for whom prior therapies are no longer effective, according to the Nov. 15, 2007, New England Journal of Medicine.
1 2 3 4   Next >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov